Quantcast
Last updated on April 24, 2014 at 16:01 EDT

Latest Neuroprotection Stories

2012-10-04 23:02:16

The porcine sciatica model can evaluate efficacy and PK/PD from the same subject and may provide more clinically relevant data at preclinical stages minimizing expensive failures. St Paul, MN (PRWEB) October 03, 2012 MD Biosciences has developed a large preclinical model of neuropathic pain for preclinical evaluation of analgesic or neuroprotective therapies. The sciatica model was developed in the pig, as the innervation is similar to that of humans, providing more clinically relevant data...

2012-08-16 01:09:08

New research published in Restorative Neurology and Neuroscience In a study published in the current issue of Restorative Neurology and Neuroscience scientists report that a therapy combining exercise with the neurovascular protective agent S-nitrosoglutathione (GSNO) improved recovery from stroke in a rat model. GSNO is a compound found naturally in the body and it has no known side effects or toxicity. "In our study, GSNO or motor exercise provided neuroprotection, reduced neuronal...

2012-08-15 01:11:59

Researchers discover compounds in green tea and chocolate may help reduce neurological complications linked to HIV Current drug therapy for patients with HIV is unable to control the complete replication of the virus in the brain. The drugs therefore do not have any effect against the complications associated with neurocognitive impairment in patients with HIV. New research by Joseph Steiner and colleagues from Johns Hopkins University has discovered that a group of plant polyphenols...

2012-07-25 02:31:21

CLARKSBURG, Md., July 25, 2012 /PRNewswire/ -- The American Health Assistance Foundation (AHAF, http://www.ahaf.org), a nonprofit organization that funds breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world. "AHAF is known for pinpointing some of the world's most...

2012-07-24 14:22:28

PHOENIX, July 24, 2012 /PRNewswire/ -- BHR Pharma announced today that it had reached its SyNAPSe® clinical trial enrollment midpoint of 590 patients during a presentation by David Okonkwo, MD, PhD, University of Pittsburgh Medical Center Brain Trauma Research Center Clinical Director, at the National Neurotrauma Society's 2012 Annual Meeting. The milestone for the global Phase 3, multi-center trial was achieved when a study subject was randomized by Songklanagarind Hospital in...

2012-06-16 00:53:10

Hope for therapy for both trauma to the peripheral nervous system and for common conditions such as diabetic neuropathy and Charcot-Marie-Tooth disease Researchers from the Peninsula College of Medicine and Dentistry, University of Exeter, in collaboration with colleagues from Rutgers University, Newark and University College London, have furthered understanding of the mechanism by which the cells that insulate the nerve cells in the peripheral nervous system, Schwann cells, protect and...

2012-05-08 06:31:10

FORT LAUDERDALE, Fla., May 8, 2012 /PRNewswire/ -- Life Extension Foundation of Fort Lauderdale, Fla., a pioneer in funding and reporting the latest anti-aging research and integrative health therapies, has announced positive results from its study to assess the effectiveness of the dietary supplement, Cognitex® with NeuroProtection Complex, in improving cognitive performance in middle-aged to elderly subjects with subjective memory complaints. (Logo:...

2012-04-23 11:16:47

Findings could lead to new therapies for stroke and epilepsy A key protein, which may be activated to protect nerve cells from damage during heart failure or epileptic seizure, has been found to regulate the transfer of information between nerve cells in the brain. The discovery, made by neuroscientists at the University of Bristol and published in Nature Neuroscience and PNAS, could lead to novel new therapies for stroke and epilepsy. The research team, led by Professor Jeremy Henley...

2012-04-23 02:29:00

PARAMUS, N.J., April 23, 2012 /PRNewswire/ -- Today, Asubio announced the initiation of a landmark Phase 2 clinical trial of SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury. In accordance with its internal focus on scientific rigor, Asubio recently discussed its endpoint development activities at a peer-attended symposium at the American Spinal Injury Association (ASIA) annual meeting. The...

2012-04-02 10:04:42

A new animal model of nerve injury has brought to light a critical role of an enzyme called Nmnat in nerve fiber maintenance and neuroprotection. Understanding biological pathways involved in maintaining healthy nerves and clearing away damaged ones may offer scientists targets for drugs to mitigate neurodegenerative diseases such as Huntington's and Parkinson's, as well as aid in situations of acute nerve damage, such as spinal cord injury. University of Pennsylvanian biologists developed...